Laura E. Niklason M.D., Ph.D.
Net Worth
Last updated:
What is Laura E. Niklason M.D., Ph.D. net worth?
The estimated net worth of Dr. Laura E. Niklason M.D., Ph.D. is at least $64,307,985 as of 20 Nov 2024. He owns shares worth $2,770,107 as insider, has earned $59,312,758 from insider trading and has received compensation worth at least $2,225,120 in Humacyte, Inc..
What is the salary of Laura E. Niklason M.D., Ph.D.?
Dr. Laura E. Niklason M.D., Ph.D. salary is $556,280 per year as Founder, Pres, Chief Executive Officer & Director in Humacyte, Inc..
How old is Laura E. Niklason M.D., Ph.D.?
Dr. Laura E. Niklason M.D., Ph.D. is 62 years old, born in 1963.
What stocks does Laura E. Niklason M.D., Ph.D. currently own?
As insider, Dr. Laura E. Niklason M.D., Ph.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Humacyte, Inc. (HUMA) | Founder, Pres, Chief Executive Officer & Director | 1,730,884 | $1.6 | $2,770,107 |
What does Humacyte, Inc. do?
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.
Laura E. Niklason M.D., Ph.D. insider trading
Humacyte, Inc.
Dr. Laura E. Niklason M.D., Ph.D. has made 28 insider trades between 2021-2024, according to the Form 4 filled with the SEC. Most recently he sold 261,369 units of HUMA stock worth $1,150,024 on 20 Nov 2024.
The largest trade he's ever made was exercising 4,875,000 units of HUMA stock on 13 Jun 2023. As of 20 Nov 2024 he still owns at least 1,730,884 units of HUMA stock.
Humacyte key executives
Humacyte, Inc. executives and other stock owners filed with the SEC:
- Dr. Heather Ledbetter Prichard Ph.D. (47) Chief Operating Officer
- Dr. Jeffrey H. Lawson M.D., Ph.D. (61) Chief Surgical Officer & Director
- Dr. Laura E. Niklason M.D., Ph.D. (62) Founder, Pres, Chief Executive Officer & Director
- Mr. Dale A. Sander (65) Chief Financial Officer, Chief Corporation Devel. Officer & Treasurer